Drugs / MT1988
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06728176 | Nov 2024 → Apr 2025 | — | Monument Therapeutics Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07226895 | Mar 2026 → Sep 2027 expected | — | Monument Therapeutics Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-06-23 | BDD Pharma Ltd | Results BDD’s Phase 1 Trial Reports Positive Phase I Results for Novel Cognitive Impairment Associated with Schizophrenia Treatment bddpharma.com ↗
Monument Therapeutics, a precision neuroscience company, today announced positive topline results from its Phase I clinical trial evaluating MT1988, a novel treatment targeting cognitive impairment associated with schizophrenia (CIAS). |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT1988 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07226895 ↗ |
| Route | Oral | “MT1988 Dose Level 1 (oral, twice daily)” NCT06728176 ↗ |